A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: ced5cbd0009bb6ddcc74f07e154a48f5f5d8f2aa
First added on: Feb 12, 2025